Analyst Debanjana Chatterjee of JonesTrading maintained a Buy rating on Pharvaris, retaining the price target of $43.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Debanjana Chatterjee has given her Buy rating due to a combination of factors including the promising expectations from the Phase 3 RAPIDe-3 trial data anticipated in the fourth quarter of 2025. The trial is set to evaluate the effectiveness of deucrictibant for immediate relief during HAE attacks, with a high likelihood of success based on previous Phase 2 results.
Chatterjee notes that deucrictibant demonstrated consistent efficacy across various assessments, indicating a faster onset of relief compared to placebo. Despite potential biases in the open-label portion of the Phase 2 trial, the drug’s competitive profile and reliable benefits suggest it will perform well in the larger, blinded RAPIDe-3 trial, supporting the path towards approval.
In another report released on October 23, H.C. Wainwright also reiterated a Buy rating on the stock with a $60.00 price target.